Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Apollomics Starts China Phase III Trial of Leukemia Drug

publication date: Nov 22, 2021

Apollomics has dosed the first patient in a China Phase III trial of uproleselan to treat relapsed or refractory acute myeloid leukemia (AML). APL-106 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells, disrupting leukemic cell resistance within the bone marrow microenvironment. In 2020, Apollomics in-licensed Greater China rights to uproleselan from GlycoMimetics in a two-drug, $189 million deal. Apollomics is headquartered in Foster City, CA with China operations in Hangzhou and Shanghai. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here